Content about Bob Jones

November 15, 2012
ReportersNotebook — Over the Counter, 11/19/12

Acura Pharmaceuticals in December will launch an immediate-release pseudoephedrine tablet under the brand name Nexafed that will help impede conversion of the tablets into methamphetamine.

SUPPLIER NEWS — Acura Pharmaceuticals in December will launch an immediate-release pseudoephedrine tablet under the brand name Nexafed that will help impede conversion of the tablets into methamphetamine. Couched as the “next generation pseudoephedrine product,” Nexafed is a 30 mg PSE hydrochloride tablet that utilizes Acura’s trademarked Impede technology. 


November 8, 2012
Acura Pharmaceuticals moves forward with plans to launch diversion-hindering PSE product

Acura Pharmaceuticals on Wednesday shared with analysts details on its launch strategy of Nexafed, a pseudoephedrine formulated such that in inhibits the diversion to methamphetamnine.

PALATINE, Ill. — Acura Pharmaceuticals on Wednesday shared with analysts details on its launch strategy of Nexafed, a pseudoephedrine formulated such that it inhibits the diversion to methamphetamnine. 

October 29, 2012
Acura Pharmaceuticals introduces PSE product that will be less attractive to 'meth cooks'

Acura Pharmaceuticals in December will launch an immediate-release pseudoephedrine tablet under the brand name Nexafed that will help impede conversion of the tablets into methamphetamine.

PALATINE, Ill. — Acura Pharmaceuticals in December will launch an immediate-release pseudoephedrine tablet under the brand name Nexafed that will help impede conversion of the tablets into methamphetamine. Couched as the "next generation pseudoephedrine product," Nexafed is a 30-mg PSE hydrochloride tablet that utilizes Acura's trademarked Impede technology. 

January 24, 2012
Oxecta now commercially available

A pain medication that utilizes Acura Pharmaceuticals' Aversion technology now is commercially available.

PALATINE, Ill. — A pain medication that utilizes Acura Pharmaceuticals' Aversion technology now is commercially available.

Acura said it was informed by Pfizer that Oxecta has hit the market in 5-mg and 7.5-mg strengths, which will be sold in 100-count bottles. Oxecta is indicated for the management of acute and chronic moderate to severe pain where the use of an opioid analgesic is appropriate.